Abstract:Importance Although substantial evidence supports buprenorphine for treatment of opioid use disorder (OUD) in controlled trials, prospective study of patient outcomes in clinical implementation of emergency department (ED) buprenorphine treatment is lacking. Objective To examine the association between buprenorphine treatment in the ED and follow-up engagement in OUD treatment 1 month later. Design, Setting, and Participants This multisite cohort study was conducted in 7 California EDs participating in a statewide implementation project to improve access to buprenorphine treatment. The study population included ED patients aged at least 18 years identified with OUD between April 1, 2021, and June 30, 2022. Data analysis was performed in October 2023. Exposure All participants were offered buprenorphine treatment for OUD (either in ED administration, prescription, or both), the uptake of which was examined as the exposure of interest. Main Outcomes and Measures The primary outcome was engagement in OUD treatment 30 days after the ED visit, determined by patient report or clinical documentation. The association of ED buprenorphine treatment with subsequent OUD treatment engagement was estimated using hierarchical generalized linear models. Results This analysis included 464 ED patients with OUD. Their median age was 36.0 (IQR, 29.0-38.7) years, and most were men (343 [73.9%]). With regard to race and ethnicity, 64 patients (13.8%) self-identified as non-Hispanic Black, 183 (39.4%) as Hispanic, and 185 as non-Hispanic White (39.9%). Most patients (396 [85.3%]) had Medicaid insurance, and more than half (262 [57.8%]) had unstable housing. Self-reported fentanyl use (242 [52.2%]) and a comorbid mental health condition (328 [71.5%]) were common. Interest in buprenorphine treatment was high: 398 patients (85.8%) received buprenorphine treatment; 269 (58.0%) were administered buprenorphine in the ED and 339 (73.1%) were prescribed buprenorphine. With regard to OUD treatment engagement at 30 days after the ED visit, 198 participants (49.7%) who received ED buprenorphine treatment remained engaged compared with 15 participants (22.7%) who did not receive ED buprenorphine treatment. An association of ED buprenorphine treatment with subsequent OUD treatment engagement at 30 days was observed (adjusted risk ratio, 1.97 [95% CI, 1.27-3.07]). Conclusions and Relevance The findings of this cohort study suggest that among patients with OUD presenting to EDs implementing low-threshold access to medications for OUD, buprenorphine treatment was associated with a substantially higher likelihood of follow-up treatment engagement 1 month later. Future research should investigate techniques to optimize both the uptake and effectiveness of buprenorphine initiation in low-threshold settings such as the ED.

Successful administration of extended-release buprenorphine in the emergency department

Emergency department buprenorphine program: staff concerns and recommended implementation strategies

Initiation of Buprenorphine in the Emergency Department: A Survey of Emergency Clinicians

Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization

Emergency Department Access to Buprenorphine for Opioid Use Disorder

A qualitative assessment of emergency physicians' experiences with robust emergency department buprenorphine bridge programs

Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review

Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department-Initiated Buprenorphine Programs

Buprenorphine prescription and treatment initiation through preemptive outreach and telehealth consultation with emergency medicine providers

Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended – Release Subcutaneous Injection: A Case Report

Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form

Surgical removal of extended-release buprenorphine depot due to adverse reactions

Methadone Initiation in the Emergency Department for Opioid Use Disorder

Impact of an Education Module on the Knowledge and Attitudes of EM Physicians Towards Prescribing Buprenorphine/Naloxone for Opioid Use Disorder

Opioid overdose after extended-release buprenorphine injection: a case report

Variability in Practice of Buprenorphine Treatment by Emergency Department Operational Characteristics

Provider Perceptions Toward Extended-Release Buprenorphine for Treatment of Opioid Use Disorder

Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment

Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol

Clinical Pharmacist with DEA License: Efforts to Increase Access to Buprenorphine in a Veteran Population